The latest addition to the AtriClip product portfolio boasts the market's lowest profile surgical LAAM device, designed to enhance accessibility and positioning.
The new cryoSPHERE MAX Probe, for Post-Operative Pain Management, provides increased surface area coverage and 60 second freeze cycles to optimize the efficiency of the Cryo Nerve Block procedure.
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2024, Provides Financial Outlook for 2025, and Announces Upcoming Analyst & Investor Day
The CEASE-AF randomized-controlled trial highlights the long-term effectiveness of Hybrid ablation, showing sustained results over 24 months and a ~33% absolute increase in freedom from atrial arrhythmias* for patients with LSPAF.
Discover more: https://t.co/Zs4xjdLb6U… https://t.co/nKLoTxSLw0
2024 was an incredible year at AtriCure! From global growth and groundbreaking innovations to key clinical milestones and impactful community outreach—there’s much to share. Watch as @AtriCureCEO Mike Carrel recaps it all and looks ahead to what 2025 has in store.
#Innovaton… https://t.co/HWtkJB175N
Taking post-op pain management to the MAX. With a 50% reduction in freeze time, the cryoSPHERE® MAX device offers a faster solution for post-op pain management.
Learn more about the latest innovation: https://t.co/L1KYPmEfOr#cryoNB
2024 was an incredible year at AtriCure! From global growth and groundbreaking innovations to key clinical milestones and impactful community outreach—there’s much to share. Watch as CEO Mike Carrel recaps it all and looks ahead to what 2025 has in store.
#Innovaton#ClinicalScience
Tune in as Electrophysiologist Dr. Chad Brodt shares insights on the ongoing HEAL-IST Trial for patients with symptomatic Inappropriate Sinus Tachycardia (IST). Discover qualification details and learn more about the trial by visiting heal-ist.com.
#IST#InnapropriateSinusTachycardia#ClinicalTrial
When it comes to durability, Hybrid ablation has demonstrated to be effective in Afib treatment.
The CEASE-AF randomized-controlled trial highlights the long-term effectiveness of Hybrid ablation, showing sustained results over 24 months and a ~33% absolute increase in freedom from atrial arrhythmias* for patients with long-standing persistent Afib.
Discover more about the CEASE-AF Trial: https://okt.to/PxwTtA#CardiacSurgery#Epeeps
Dr. Pouya Hemmati and the team at Baptist Health Medical Center Little Rock are starting the new year strong with their first case using the EPi-Sense ST™ device!
This innovative device enhances deflection and control for epicardial Afib ablation, offering a new treatment option for patients with long-standing persistent Afib.
Learn more about EPi-Sense ST: https://okt.to/QmuBhY#HybridAFTherapy#Afib
2024 was an incredible year at AtriCure! From global growth and groundbreaking innovations to key clinical milestones and impactful community outreach—there’s much to share. Watch as CEO Michael Carrel recaps it all and looks ahead to what 2025 has in store.
#Innovaton#ClinicalScience
Taking post-op pain management to the MAX. With a 50% reduction in freeze time, the cryoSPHERE® MAX device offers a faster solution for post-op pain management.
Learn more about the latest innovation: https://okt.to/GfsY5y#cryoNB
social media channels to keep updated on the latest at AtriCure.
Dorsey's Cardiac Testimonial
Duration: 3:44
Exclusion that Results in Electrical Isolation
Duration: 00:43
Blake’s Pectus Excavatum Full Journey
Duration: 6:29
About the 3D Heart Education App
Duration: 00:37